[go: up one dir, main page]

GB9911417D0 - Furanone derivatives as inhibitors of cathepsin s - Google Patents

Furanone derivatives as inhibitors of cathepsin s

Info

Publication number
GB9911417D0
GB9911417D0 GBGB9911417.5A GB9911417A GB9911417D0 GB 9911417 D0 GB9911417 D0 GB 9911417D0 GB 9911417 A GB9911417 A GB 9911417A GB 9911417 D0 GB9911417 D0 GB 9911417D0
Authority
GB
United Kingdom
Prior art keywords
cathepsin
inhibitors
furanone derivatives
furanone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9911417.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Holding Ltd
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Priority to GBGB9911417.5A priority Critical patent/GB9911417D0/en
Publication of GB9911417D0 publication Critical patent/GB9911417D0/en
Priority to MYPI20002178A priority patent/MY130768A/en
Priority to PCT/GB2000/001894 priority patent/WO2000069855A2/en
Priority to PT00929721T priority patent/PT1178986E/pt
Priority to JP2000618272A priority patent/JP2002544274A/ja
Priority to AU47722/00A priority patent/AU763694B2/en
Priority to AT00929721T priority patent/ATE260274T1/de
Priority to DE60008524T priority patent/DE60008524T2/de
Priority to SI200030360T priority patent/SI1178986T1/xx
Priority to MXPA01011872A priority patent/MXPA01011872A/es
Priority to IL14640988A priority patent/IL146409A0/xx
Priority to CA002374297A priority patent/CA2374297A1/en
Priority to IL14640900A priority patent/IL146409A/xx
Priority to EP00929721A priority patent/EP1178986B1/de
Priority to BR0010553-8A priority patent/BR0010553A/pt
Priority to ES00929721T priority patent/ES2215048T3/es
Priority to EP20040002432 priority patent/EP1413580A1/de
Priority to DK00929721T priority patent/DK1178986T3/da
Priority to ARP000102445A priority patent/AR024040A1/es
Priority to US10/015,186 priority patent/US20030203900A1/en
Priority to US10/678,947 priority patent/US20050070598A1/en
Priority to US10/853,408 priority patent/US20040229915A1/en
Priority to US10/929,133 priority patent/US20050020588A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
GBGB9911417.5A 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s Ceased GB9911417D0 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
GBGB9911417.5A GB9911417D0 (en) 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s
MYPI20002178A MY130768A (en) 1999-05-18 2000-05-17 Furanone derivatives as inhibitors of cathepsin s
DK00929721T DK1178986T3 (da) 1999-05-18 2000-05-18 Furanonderivater som inhibitorer af cathepsin S
IL14640988A IL146409A0 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s
EP00929721A EP1178986B1 (de) 1999-05-18 2000-05-18 Furanonderivate als inhibitoren von cathepsin s
JP2000618272A JP2002544274A (ja) 1999-05-18 2000-05-18 カテプシンｓのインヒビターとしてのフラノン誘導体
AU47722/00A AU763694B2 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of Cathepsin S
AT00929721T ATE260274T1 (de) 1999-05-18 2000-05-18 Furanonderivate als inhibitoren von cathepsin s
DE60008524T DE60008524T2 (de) 1999-05-18 2000-05-18 Furanonderivate als inhibitoren von cathepsin s
SI200030360T SI1178986T1 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s
MXPA01011872A MXPA01011872A (es) 1999-05-18 2000-05-18 Derivados de furanona como inhibidores de la catepsina s.
PCT/GB2000/001894 WO2000069855A2 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s
CA002374297A CA2374297A1 (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s
IL14640900A IL146409A (en) 1999-05-18 2000-05-18 Furanone derivatives as inhibitors of cathepsin s
PT00929721T PT1178986E (pt) 1999-05-18 2000-05-18 Derivados da furanona como inibidores da catepsina s
BR0010553-8A BR0010553A (pt) 1999-05-18 2000-05-18 Derivados de furanona como inibidores de catepsina s
ES00929721T ES2215048T3 (es) 1999-05-18 2000-05-18 Derivados de furanona inhibidores de la catepsina s.
EP20040002432 EP1413580A1 (de) 1999-05-18 2000-05-18 Furanone Derivate als Inhibitoren von Cathepsin S
ARP000102445A AR024040A1 (es) 1999-05-18 2000-05-19 Derivados de furanona como inhibidores de la catepsina s
US10/015,186 US20030203900A1 (en) 1999-05-18 2001-11-16 Cysteine protease inhibitors
US10/678,947 US20050070598A1 (en) 1999-05-18 2003-10-03 Cysteine protease inhibitors
US10/853,408 US20040229915A1 (en) 1999-05-18 2004-05-24 Cysteine protease inhibitors
US10/929,133 US20050020588A1 (en) 1999-05-18 2004-08-27 Cysteine protease inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911417.5A GB9911417D0 (en) 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s

Publications (1)

Publication Number Publication Date
GB9911417D0 true GB9911417D0 (en) 1999-07-14

Family

ID=10853598

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9911417.5A Ceased GB9911417D0 (en) 1999-05-18 1999-05-18 Furanone derivatives as inhibitors of cathepsin s

Country Status (16)

Country Link
EP (2) EP1178986B1 (de)
JP (1) JP2002544274A (de)
AR (1) AR024040A1 (de)
AT (1) ATE260274T1 (de)
AU (1) AU763694B2 (de)
BR (1) BR0010553A (de)
CA (1) CA2374297A1 (de)
DE (1) DE60008524T2 (de)
DK (1) DK1178986T3 (de)
ES (1) ES2215048T3 (de)
GB (1) GB9911417D0 (de)
IL (2) IL146409A (de)
MX (1) MXPA01011872A (de)
MY (1) MY130768A (de)
PT (1) PT1178986E (de)
WO (1) WO2000069855A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001258543A1 (en) * 2000-05-17 2001-11-26 Medivir Uk Limited Branched amino acids
JP2004520439A (ja) * 2000-11-17 2004-07-08 メディヴィル・アクチボラグ システインプロテアーゼインヒビター
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
CA2433520A1 (en) 2000-12-22 2002-07-04 Axys Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
US7132449B2 (en) 2001-01-17 2006-11-07 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
WO2002057249A1 (en) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
JP4608183B2 (ja) 2001-01-17 2011-01-05 アミュラ テラピューティクス リミテッド クルジパインおよび他のシステインプロテアーゼの阻害剤
WO2002057246A2 (en) * 2001-01-17 2002-07-25 Amura Therapeutics Limited Inhibitors of cruzipain and other cysteine proteases
PL369312A1 (en) * 2001-09-14 2005-04-18 Aventis Pharmaceuticals Inc. Novel compounds and compositions as cathepsin inhibitors
JP2005508979A (ja) * 2001-10-29 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド システインプロテアーゼの可逆性インヒビターとして有用な化合物
CA2467391A1 (en) 2001-11-14 2003-05-22 Aventis Pharmaceuticals Inc. Oligopeptides and compositions containing them as cathepsin s inhibitors
EP1483241A4 (de) 2002-03-08 2006-12-13 Bristol Myers Squibb Co Cyclische derivate als modulatoren der chemokinrezeptoraktivität
WO2004007501A1 (en) * 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
EP1575576A2 (de) 2002-09-24 2005-09-21 Novartis AG Organische verbindungen
US7297714B2 (en) * 2003-10-21 2007-11-20 Irm Llc Inhibitors of cathepsin S
WO2005082876A1 (en) * 2004-03-01 2005-09-09 Medivir Uk Ltd C-5 substituted furanone dipeptide cathepsin s inhibitors
WO2006064286A1 (en) * 2004-12-13 2006-06-22 Medivir Uk Ltd Cathepsin s inhibitors
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
EP1916248A1 (de) * 2006-10-24 2008-04-30 Medivir Ab Furanonderivate als Inhibitoren der Cysteinprotease
AU2008221036B2 (en) 2007-02-28 2014-03-20 Sanofi Imaging probes
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
WO2020201572A1 (en) 2019-04-05 2020-10-08 Université De Bretagne Occidentale Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2111930A1 (en) * 1992-12-25 1994-06-26 Ryoichi Ando Aminoketone derivatives
AU723447B2 (en) * 1996-04-22 2000-08-24 Brigham And Women's Hospital Suppression of immune response via inhibition of cathepsin S
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios

Also Published As

Publication number Publication date
DK1178986T3 (da) 2004-07-05
ATE260274T1 (de) 2004-03-15
PT1178986E (pt) 2004-07-30
MXPA01011872A (es) 2003-09-04
IL146409A0 (en) 2002-07-25
AU4772200A (en) 2000-12-05
CA2374297A1 (en) 2000-11-23
DE60008524T2 (de) 2004-12-23
EP1413580A1 (de) 2004-04-28
AU763694B2 (en) 2003-07-31
WO2000069855A3 (en) 2001-02-08
ES2215048T3 (es) 2004-10-01
WO2000069855A2 (en) 2000-11-23
DE60008524D1 (de) 2004-04-01
BR0010553A (pt) 2002-07-02
EP1178986A2 (de) 2002-02-13
AR024040A1 (es) 2002-09-04
EP1178986B1 (de) 2004-02-25
MY130768A (en) 2007-07-31
JP2002544274A (ja) 2002-12-24
IL146409A (en) 2005-11-20

Similar Documents

Publication Publication Date Title
IL146409A0 (en) Furanone derivatives as inhibitors of cathepsin s
SI1686119T1 (sl) Derivati pirimidin-5-ona kot inhibitorji ldl-pla2
HK1208446A1 (en) Derivatives of uk-2a uk-2a
IL153325A0 (en) Colchinol derivatives as angiogenesis inhibitors
IL153484A0 (en) Colchinol derivatives as angiogenesis inhibitors
IL152830A0 (en) Arylmethylamine derivatives for use as tryptase inhibitors
ZA200204397B (en) Nitrile derivatives as cathepsin K inhibitors.
PL351261A1 (en) Derivatives of indigoid bisindoles
HUP0202450A3 (en) N-heterocyclic derivatives as nos inhibitors
AU2560300A (en) Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
PL357780A1 (en) Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain
EP1478634A4 (de) Furanonderivate
PL354979A1 (en) Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
GB0026578D0 (en) Heterocyclic derivatives useful as pharmaceutical agents
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
IL145600A0 (en) Use of maduraphthalazine derivatives as inhibitors of pro-inflammatory cytokins
AU8465701A (en) Use of vitamin d derivatives as bone resorption inhibitors
SI1178986T1 (en) Furanone derivatives as inhibitors of cathepsin s
AU4917000A (en) Oligohydroxyl substituted benzofuran-3-yl and pyridofuranylurea derivatives as phosphodiesterase iv inhibitors
WO2002020465A3 (en) GAMMA CETOACID DIPEPTIDES AS CASPASE-3 INHIBITORS
AU2001272490A1 (en) Use of galiella lactone
IL144045A0 (en) Oxetanone derivatives
AU2002215766A1 (en) Gamma-ketoacid dipeptide derivatives as inhibitors of caspase-3

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)